logo
ResearchBunny Logo
Spatial proteomics identifies JAKi as treatment for a lethal skin disease

Medicine and Health

Spatial proteomics identifies JAKi as treatment for a lethal skin disease

T. M. Nordmann, H. Anderton, et al.

A groundbreaking study by Thierry M. Nordmann and colleagues reveals that targeting JAK inhibitors could be a transformative therapy for toxic epidermal necrolysis (TEN), a severe drug-induced skin reaction. Through deep visual proteomics analysis, the research identified key activation signatures in TEN, demonstrating the promise of JAK inhibitors in improving patient outcomes.

00:00
00:00
~3 min • Beginner • English
Abstract
Toxic epidermal necrolysis (TEN) is a fatal drug-induced skin reaction triggered by common medications and is an emerging public health issue1,3. Patients with TEN undergo severe and sudden epidermal detachment caused by keratinocyte cell death. Although molecular mechanisms that drive keratinocyte cell death have been proposed, the main drivers remain unknown, and there is no effective therapy for TEN. Here, to systematically map molecular changes that are associated with TEN and identify potential druggable targets, we utilized deep visual proteomics7,8, which provides single-cell-based, cell-type-resolution proteomics7,8. We analysed formalin-fixed, paraffin-embedded archived skin tissue biopsies of three types of cutaneous drug reactions with varying severity and quantified more than 5,000 proteins in keratinocytes and skin-infiltrating immune cells. This revealed a marked enrichment of type I and type II interferon signatures in the immune cell and keratinocyte compartment of patients with TEN, as well as phosphorylated STAT1 activation. Targeted inhibition with the pan-JAK inhibitor tofacitinib in vitro reduced keratinocyte-directed cytotoxicity. In vivo oral administration of tofacitinib, baricitinib or the JAK1-specific inhibitors abrocitinib or upadacitinib ameliorated clinical and histological disease severity in two distinct mouse models of TEN. Crucially, treatment with JAK inhibitors (JAKi) was safe and associated with rapid cutaneous re-epithelialization and recovery in seven patients with TEN. This study uncovers the JAK/STAT and interferon signalling pathways as key pathogenic drivers of TEN and demonstrates the potential of targeted JAKi as a curative therapy.
Publisher
Nature
Published On
Oct 16, 2024
Authors
Thierry M. Nordmann, Holly Anderton, Akito Hasegawa, Lisa Schweizer, Peng Zhang, Pia-Charlotte Stadler, Ankit Sinha, Andreas Metousis, Florian A. Rosenberger, Maximilian Zwiebel, Takashi K. Satoh, Florian Anzengruber, Maximilian T. Strauss, Maria C. Tanzer, Yuki Saito, Ting Gong, Marvin Thielert, Haruna Kimura, Natasha Silke, Edwin H. Rodriguez, Gaetana Restivo, Hong Ha Nguyen, Annette Gross, Laurence Feldmeyer, Lukas Joerg, Mitchell P. Levesque, Peter J. Murray, Saskia Ingen-Housz-Oro, Andreas Mund, Riichiro Abe, John Silke, Chao Ji, Lars E. French, Matthias Mann
Tags
toxic epidermal necrolysis
JAK inhibitors
deep visual proteomics
keratinocyte cytotoxicity
disease severity
drug reactions
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny